ContextVision – Strong Q3 with solid sales, good inflow of new customers and first product in digital pathology enters beta-testing phase

STOCKHOLM – October 24, 2019 – ContextVision, a medical technology software company specializing in image analysis and artificial intelligence, has seen a strong third quarter in 2019 as new customers have been added and the first product in digital pathology has entered the beta-testing phase. Q3 sales reached 23 MSEK and total sales are growing […]
Read More

ContextVision – Second quarter saw commercial release of first AI-based product, Altumira™, Digital Pathology on track and record sales

STOCKHOLM – August 15, 2019 – ContextVision, a medical technology software company specializing in image analysis and artificial intelligence, continued to advance its artificial intelligence portfolio in the second quarter 2019. The company’s AI-based product Altumira™ for X-ray is now commercially available and INIFY Prostate for digital pathology will soon move to beta testing in […]
Read More

ContextVision’s Deep Learning experts will hold an oral presentation at the Medical Imaging & Deep Learning conference in London July 8–10

This paper presents an interesting and novel idea of a deep learning (DL) framework to segment potentially cancerous areas in prostate biopsies using semi-automatically generated data. The application of this paper is quite innovative and the proposed method seems to be a direct assistance to the clinical routine.
Read More

Meet us at CMEF, May 14–17, 2019

Meet us at CMEF, April 11–14, 2018, Shanghai, China. Hall 5.1, Booth D10. Contact us: John Xie 谢家农 / Sales Manager, phone +86 13 801 333 835, e-mail 
Read More

ContextVision sees strong sales, continues focus on launch of AI-based digital pathology

ContextVision, a medical technology software company specializing in image analysis and artificial intelligence, reported strong sales in Q1, reaching 21.1 MSEK, 9% higher than the first quarter last year. The company reports positive feedback from user tests within digital pathology and continues to proceed with product development for this fast-growing market.
Read More